Sign In
2 May 2014 09:30
Directors Shareholdings
London, 2 May 2014 Sinclair IS Pharma plc (AIM:SPH.L), the international specialty pharma company, announces that further to today's Admission of 62,500,000 new ordinary shares ("Placing Shares") relating to the Placing and Acquisition announced 15 April 2014 and subsequent passing of resolutions at a General Meeting on 1 May 2014, certain Directors have subscribed for Placing Shares in the Placing as set out below:
Name | Placing Shares subscribed for at 32p per share | Ordinary shares held post Admission | Percentage of voting rights post Admission (%) |
Jean-Charles Tschudin | 500,000 | 2,000,117 | 0.40 |
Stuart Swanson | 3,125,000 | 7,980,854 | 1.54 |
Ends
For further information please contact:
Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920
Chris Spooner
Alan Olby
Robert Taylor
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Clare Terlouw
Notes to Editors:
About Sinclair IS Pharma plc - see www.sinclairispharma.com
Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology, in particular Aesthetics, Wound care, and Skin care. The Group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.
Follow the stocks
